NUBYTIDE Trademark

Trademark Overview


On Monday, November 27, 2023, a trademark application was filed for NUBYTIDE with the United States Patent and Trademark Office. The USPTO has given the NUBYTIDE trademark a serial number of 98286932. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, June 26, 2024. This trademark is owned by Cenna Biosciences Inc.. The NUBYTIDE trademark is filed in the Pharmaceutical Products category with the following description:

Medication for Alzheimer's disease
nubytide

General Information


Serial Number98286932
Word MarkNUBYTIDE
Filing DateMonday, November 27, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateWednesday, June 26, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesMedication for Alzheimer's disease

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, January 18, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCenna Biosciences Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLa Jolla, CA 92037

Trademark Events


Event DateEvent Description
Thursday, November 30, 2023NEW APPLICATION ENTERED
Thursday, January 18, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 26, 2024ASSIGNED TO EXAMINER
Wednesday, June 26, 2024NON-FINAL ACTION WRITTEN
Wednesday, June 26, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 26, 2024NON-FINAL ACTION E-MAILED